These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3529954)

  • 1. Stability and reproducibility of the biologic activity of premixed short-acting and intermediate-acting insulins.
    Jawadi MH; Ho LS
    Am J Med; 1986 Sep; 81(3):467-71. PubMed ID: 3529954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effects of mixing short- and intermediate-acting insulins in the treatment of non-insulin-dependent diabetes.
    Best JD; Ley CJ; Strauss BJ; Alford FP; Aitken PM
    Med J Aust; 1987 Jun; 146(12):621-3, 627. PubMed ID: 3306298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of intermediate-acting insulin preparations to daytime insulin treatment.
    Robert JJ; Chevenne D; Debray M
    Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing effect of mixing insulins by glucose-clamp technique in subjects with diabetes mellitus.
    Colagiuri S; Villalobos S
    Diabetes Care; 1986; 9(6):579-86. PubMed ID: 3542452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mixing short- and intermediate-acting insulins on absorption course and biologic effect of short-acting preparation.
    Forlani G; Santacroce G; Ciavarella A; Capelli M; Mattioli L; Vannini P
    Diabetes Care; 1986; 9(6):587-90. PubMed ID: 3542453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixing short and intermediate acting insulins in the syringe: effect on postprandial blood glucose concentrations in type I diabetics.
    Heine RJ; Bilo HJ; Sikkenk AC; van der Veen EA
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):204-5. PubMed ID: 3917752
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of insulin mixtures in type I diabetics: influence of the intermediate acting insulin on the action of short acting insulin.
    Goicolea I; Quiroga A; Vazquez JA
    Diabete Metab; 1987; 13(4):467-70. PubMed ID: 3315768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.
    Koivisto VA; Tuominen JA; Ebeling P
    Diabetes Care; 1999 Mar; 22(3):459-62. PubMed ID: 10097929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system].
    Chen SF; Li H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug; 32(8):827-9. PubMed ID: 22093477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment persistence in the use of basal insulins in Poland and Germany
.
    Rathmann W; Czech M; Franek E; Kostev K
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
    Lin JC; Shau WY; Lai MS
    Clin Ther; 2014 Sep; 36(9):1255-68. PubMed ID: 25082730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
    Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
    Xu S; Liu X; Ming J; Ji Q
    Trials; 2016 Mar; 17():160. PubMed ID: 27009108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubility changes on mixing short- and long-acting insulin preparations.
    Havlik I; Galasko G; Alberts E; Furman KI; Seftel HC
    S Afr Med J; 1988 Mar; 73(6):361-2. PubMed ID: 3281288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins.
    Heine RJ; Bilo HJ; Fonk T; van der Veen EA; van der Meer J
    Diabetologia; 1984 Dec; 27(6):558-62. PubMed ID: 6397384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biphasic insulin aspart (NovoMix 50)].
    Radermecker RP; Scheen AJ
    Rev Med Liege; 2008 Nov; 63(11):688-92. PubMed ID: 19112996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the activity of Rapitard and Actraphane insulins.
    Colagiuri S; Jones S
    Diabete Metab; 1988 Dec; 14(6):689-92. PubMed ID: 3073090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.